MDCX — Medicus Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1997296 ·
Last close
$0.10
Market Cap
$6.44M
52W High
$2.78
52W Low
$0.09
ADV30
8,042,003
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -11,478,789 | -11,617,705 | 27,116,185 | 15,174,128 | 28,841,149 |
| Mar 2026 | 0 | — | -8,597,077 | -9,042,143 | 7,426,911 | 6,365,624 | 5,999,017 |
| Dec 2025 | 0 | — | -7,790,600 | -8,184,411 | 10,061,377 | 8,705,218 | 10,024,066 |
| Sep 2025 | 0 | — | -15,426,340 | -15,981,312 | 9,977,661 | 8,662,091 | 10,782,551 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,805,463
Investing CF
$0
Financing CF
$35,005,835
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.28
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-73,390,261
Inventory
—
Receivables
$14,000
ST Investments
—
EBIT TTM
$-37,900,627
Pretax Income TTM
$-39,384,264
Interest Exp TTM
$1,170,822
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,359,302 | -35,444,215 | 10,061,377 | 10,024,066 | -67,554 | -22,776,769 |
| Dec 2024 | 0 | -11,180,902 | -11,155,516 | 5,646,878 | 2,512,174 | 3,134,704 | -10,247,231 |
| Dec 2023 | 0 | -2,658,365 | -5,314,765 | 1,893,057 | 781,609 | 1,111,448 | -4,158,264 |
| Dec 2022 | 0 | -978,416 | -1,692,382 | 282,652 | 12,480,684 | -12,198,032 | -1,057,103 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-51,221,248
OpCashFlow TTM
—
Assets (Latest)
$7,426,911
Forward EPS
$-0.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALZN | Alzamend Neuro, Inc. | $6.47M | $1.34 | — |
| XCUR | EXICURE, INC. | $6.55M | $1.00 | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $6.56M | $0.50 | — |
| INNPF | INNOCAN PHARMA Corp | $6.30M | $1.40 | — |
| LEXX | Lexaria Bioscience Corp. | $6.74M | $3.20 | — |
News headlines (Yahoo Finance, 1h cache)
Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing
2026-10-08 14:41 · Yahoo
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
2026-10-08 13:04 · Yahoo
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
2026-10-08 12:00 · Yahoo
Medicus Pharma seeks FDA alignment on streamlined Phase 2b/3 Teverelix study
2026-10-05 17:49 · Yahoo
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
2026-09-29 12:59 · Yahoo
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
2026-09-29 11:30 · Yahoo
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
2026-09-21 13:50 · Yahoo
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
2026-09-21 11:32 · Yahoo
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
2026-09-21 11:30 · Yahoo
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
2026-09-12 14:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.